Every child deserves the chance to receive the right diagnosis and the right treatment – regardless of where he or she is born. Yet for millions of children living with rare diseases, this remains an unmet need. Families often spend years searching for answers while valuable opportunities for treatment, prevention, and informed care may be lost. Christoph Klein, MD, PhD explains Dr. von Hauner Children’s Hospital’s mission to provide equitable access to advanced healthcare.
Recent advances in genomics, bioinformatics, and precision medicine are transforming this reality. What was once impossible is increasingly becoming routine: identifying the molecular cause of disease, connecting patients to targeted therapies, and providing families with clarity and hope.
The challenge is no longer scientific possibility, but equitable access. Building sustainable diagnostic capacity, fostering international collaboration, and sharing knowledge across borders are essential to ensure that the benefits of precision medicine reach children everywhere. Knowledge should travel, not children.
For generations, excellence in medicine has been concentrated in specialized clinical centres. Institutions such as the Dr. von Hauner Children’s Hospital of LMU Munich have demonstrated how clinical expertise, scientific discovery, and innovation can transform the lives of children with rare and complex diseases. Yet the future of precision medicine should not depend on moving patients across countries and continents. The future of medicine will depend on sharing knowledge, building partnerships, and creating networks that allow expertise to reach children wherever they live.
At LMU Munich, we are convinced that precision medicine is entering a new era. Advances in genomics, molecular diagnostics, artifcial intelligence, and translational science are providing unprecedented opportunities to reinterpret disease phenotypes, understand disease
mechanisms and guide individualized curative care. What began as a revolution in rare disease diagnostics is increasingly reshaping paediatrics as a whole.
Guided by our conviction that insights from rare diseases often illuminate common diseases “from rare to common“, we believe that critical insights in rare disease research have profound implications for diagnosis, prevention and treatment across medicine, for children and adults alike.
However, technology alone is not enough.
The true value of molecular diagnostics emerges when genomic information is interpreted in the context of comprehensive clinical expertise, deep biological understanding, and multidisciplinary collaboration. No single institution possesses all the knowledge required to solve every complex disease. Progress increasingly depends on connecting expertise across disciplines, institutions, and countries. We are challenged to build networks of networks that transcend traditional healthcare structures.
Vision to Cure
Care. Connect.
Create. Cure.
Care for every child.
Create knowledge across
borders. Accelerate the path
to cure.
The future of medicine will
be built through networks of
networks.
Vision to Cure fosters global partnerships that connect expertise, data, innovation, and care to improve
outcomes for children worldwide.
Knowledge should travel, not children.
Our conviction that knowledge – not children – should travel has shaped our commitment to international collaboration and global alliances. Through mutual trust and partnerships with hospitals, universities, physicians, scientists, patient organizations, and philanthropic initiatives worldwide, we seek to ensure that children can benefit from world-class expertise while remaining close to their families and communities.
Together with philanthropic partners and international collaborators, we support the broader mission of advancing precision child health through education, scientific exchange, and the development of sustainable partnerships. Together, we seek to accelerate the flow of knowledge, expertise, and innovation across borders. Geography should never determine access to knowledge.
This vision is particularly relevant for the Middle East, where ambitious investments in healthcare, genomics, and biomedical innovation are creating new opportunities to improve outcomes for children with rare and complex diseases. We believe that the combination of local clinical excellence and global scientific collaboration can create powerful new models of care for future generations.
More than one thousand years ago, the physician and philosopher Ibn Sina – known in the West as Avicenna – argued that medicine should seek to understand the causes of disease rather than merely describe its manifestations. His ideas travelled across continents and influenced generations of physicians from Central Asia to Europe.
Today, in the era of genomic medicine, this spirit remains as important as ever. Knowledge should travel, not children.
Through scientific collaboration, cut-ting-edge molecular diagnostics, shared expertise, and trustworthy global partnerships, we can ensure that every child benefits from the best available knowledge – wherever they live. Clinical care should remain local. Knowledge should be global. The future of precision child health will be built not by individual institutions, but by partnerships dedicated to every child, everywhere.
About the author
Christoph Klein, MD PhD, is Chair of Pediatrics at the Dr. von Hauner Children’s Hospital, Ludwig Maximilian University (LMU) Munich, Germany. A physician-scientist specializing in rare diseases, immunology, and genomic medicine, he and his team have contributed to the discovery of numerous human diseases and the development of novel therapeutic strategies. He is founder of the Care-for-Rare initiative and Director of the Comprehensive Childhood Research Center (CCRC), dedicated to advancing precision medicine and improving outcomes for children worldwide.
